摘要
目的:观察不同剂量布地奈德(普米克令舒)联合沙丁胺醇(万托林)雾化吸入治疗哮喘急性发作的临床疗效及安全性。方法:80例哮喘轻-中度发作儿童随机分为3组:A组26例于常规治疗基础上予布地奈德0.5mg与沙丁胺醇雾化液联合雾化吸入治疗;B组29例于常规治疗基础上予布地奈德1mg与沙丁胺醇雾化液联合雾化吸入治疗;对照组25例予琥珀酸氢化可的松加常规治疗。治疗前后分别进行临床症状评分、肺功能检测并观察不良反应。结果:各组患者治疗后临床症状评分、肺功能指标均较治疗前显著改善(P<0.05及P<0.01);各组治疗后指标比较,仅B组治疗后FEV1%pred、PEF%pred较A组改善更明显(P<0.05)。A组及B组不良反应明显少于对照组。结论:不同剂量布地奈德联合沙丁胺醇雾化吸入均能改善哮喘急性发作儿童肺功能及临床症状,与全身使用糖皮质激素疗效相近,但不良反应明显减少。足量布地奈德雾化吸入治疗儿童哮喘急性发作可能较常规剂量疗效更佳。
OBJECTIVE：To observe the clinical efficacy and safety of aerosol inhalation therapy of different doses of Pulmicort Respules combined with Atrovent on acute exacerbation of asthma.METHODS：80 patients with acute exacerbation of mild to moderate asthma were randomly divided into 3 groups：Group A（n = 26） received conventional treatment in combination with inhaled Pulmicort Respules（0.5 mg） and Atrovent;Group B（n = 29） received conventional treatment in combination of inhaled Pulmicort Respules（1mg） and Atrovent,and another 25 cases in control group received conventional treatment plus Hydrocortisone Succinate.The clinical symptom scores,pulmonary function and adverse drug reactions before and after treatment were recorded.RESULTS：After treatment,the clinical symptom scores and pulmonary function in all groups improved significantly as compared with before treatment（P 0.05,P 0.01）;however,Group B showed significantly better improvement in FEV1 % pred and PEF % pred than in Group A（P 0.05）.Group A and Group B presented with significantly less side effects than did the control group.CONCLUSION：Aerosol inhalation therapy of combing different doses of Pulmicort Respules with Atrovent can improve pulmonary function and clinical symptom in patients with acute exacerbation of asthma and it is similar to systemic administration of hydrocortisone but with fewer side effects.Aerosol inhalation therapy of full dose of Pulmicort Respules is possibly more efficacious than is normal doses for acute exacerbation of asthma.
出处
《中国医院用药评价与分析》
2010年第6期536-538,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
作者简介
主管药师,研究方向：临床药学。E-mail：bafyyj@yahoo.com．cn
